Celcuity Inc: Clinical Trials

2 trials sponsored by Celcuity Inc, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 active not recruiting, 1 recruiting. 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 32Active not recruiting 1, Recruiting 1

Follow Celcuity Inc: new trials by email

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Arm A: Gedatolisib + Palbociclib + Fulvestrant, Arm B: Ribociclib + Fulvestrant, Arm C: Gedatolisib + Palbociclib + Letrozole - Breast Cancer
Phase 3RecruitingCelcuity Inc11802025-07-242026-10-09
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
Gedatolisib, Palbociclib, Fulvestrant - Breast Cancer
Phase 3Active not recruitingCelcuity Inc7012022-12-082026-02-10

Conditions studied

Breast Neoplasms (2)  ·  Neoplasm Metastasis (2)

Interventions

Fulvestrant (2)  ·  gedatolisib (2)  ·  palbociclib (2)  ·  Alpelisib (1)  ·  Letrozole (1)  ·  ribociclib (1)

Countries

Argentina (2)  ·  Australia (2)  ·  Belgium (2)  ·  Bulgaria (2)  ·  Czechia (2)  ·  France (2)  ·  Germany (2)  ·  Greece (2)  ·  Hungary (2)  ·  Italy (2)  ·  Mexico (2)  ·  Poland (2)  ·  Romania (2)  ·  South Korea (2)  ·  Spain (2)

Top investigators

Nadene Zack (1)

Results publications

PMID 41802242